Soldotna Pharmaceutical Dinner - AstraZeneca

Beyond the Benchmark: Are We Meeting Today’s GOLD Standard?

Join AstraZeneca for a dynamic program on the ongoing burden of COPD and the unmet needs of patients still onICS/LABA, despite GOLD no longer recommending it for maintenance.

We will be exploring the latest GOLD updates, including new algorithms for transitioning off ICS/LABA, and reviewing clinical evidence supporting BREZTRI’s role in reducing exacerbations and improving lung function.

Topics we will cover

• Burden of COPD and unmet needs of patients onICS/LABA
• 2025 GOLD Report recommendations, includingthe new algorithm for transitioning patients offICS/LABA 

BREZTRI Clinical Review

• Mechanism of action
• Lung deposition data
• Efficacy and safety data from KRONOS andETHOS pivotal trials

Presented ByDavid PhamM.D., F.C.C.P.Comprehensive Pulmonary Medical Group in Westminster, California;Founder/Medical Director - Allianz Research Institute; Chief Executive Officer and Founder Pulmonary Clinical Research in Westminster, California

RSVP
Jenna Hansen (907) 398-5800 by 2/21/2026 

Additional information can be found here: Program Flyer